Table of Contents
1. NAME OF THE MEDICINAL PRODUCT
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
3. PHARMACEUTICAL FORM
4. CLINICAL PARTICULARS
4.1 Therapeutic indications
4.2 Posology and method of administration
4.3 Contraindications
4.4 Special warnings and precautions for use
4.5 Interaction with other medicinal products and other forms of interaction
4.6 Pregnancy and lactation
4.7 Effects on ability to drive and use machines
4.8 Undesirable effects
4.9 Overdose
5. PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
5.2 Pharmacokinetic properties
5.3 Preclinical safety data
6. PHARMACEUTICAL PARTICULARS
6.1 List of excipients
6.2 Incompatibilities
6.3 Shelf life
6.4 Special precautions for storage
6.5 Nature and contents of container
6.6 Special precautions for disposal and other handling
7. MARKETING AUTHORISATION HOLDER
8. MARKETING AUTHORISATION NUMBER(S)
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
10. DATE OF REVISION OF THE TEXT
|
|
150 mg pancreatin, equivalent to:
|
|
|
|
Lipase
|
10,000 Ph. Eur. units
|
|
Amylase
|
8,000 Ph. Eur. units
|
|
Protease
|
600 Ph. Eur. units
|
For a full list of excipients, see section 6.1.
|
|
|
|
Gastro-resistant capsules, hard.
Size 2 hard gelatin capsules with brown caps and colourless bodies filled with gastro-resistant brown granules.
|
|
|
|
Pancreatic exocrine deficiency.
|
|
|
|
Adults (including the elderly) and children:
Initially one to two capsules with meals. Dose increases, if required, should be added slowly, with careful monitoring of response and symptomatology. The daily dose of pancreatic enzymes for most patients should remain below 2500 units of lipase per kilogram per meal (10,000 units per kilogram per day), and that higher doses should be used with caution and only if quantitative measures demonstrate substantially improved absorption with such treatment. This applies particularly to young children.
It is important to ensure adequate hydration of patients at all times whilst dosing Creon.
The capsules can be swallowed whole, or for ease of administration they may be opened and the granules taken with fluid or soft food. If the granules are mixed with food, it is important that they are taken immediately, otherwise dissolution of the enteric coating may result. In order to protect the enteric coating, it is important that the granules are not crushed or chewed (see 4.8 Undesirable Effects).
Colonic damage has been reported in patients with cystic fibrosis taking high doses of pancreatic enzyme supplements (see 4.8 Undesirable effects).
|
|
|
|
Use in patients with known hypersensitivity to porcine proteins.
|
|
|
|
The product is of porcine origin.
Oral medications should not be administered during the early stages of acute pancreatitis.
|
|
|
|
There are no adequate data from the use of Creon in pregnant women. Animal studies are insufficient with respect to effects on pregnancy and embryonal/foetal development, parturition/ and postnatal development. The potential risk for humans is unknown. Creon should not be used during pregnancy or lactation unless clearly necessary but if required should be used in doses providing adequate nutritional status (see warnings about high dose sections 4.2 and 4.8.).
|
|
|
|
1. Rarely, cases of hyper-uricosuria and hyper-uricaemia have been reported with very high doses of pancreatin.
2. Meconium ileus type obstructive symptoms and cases of colonic stricture resulting in bowel re-section, have been seen with high doses of pancreatic enzyme supplements. Similar problems have not occurred to date with this product. However, unusual abdominal symptoms or changes in abdominal symptoms should be reviewed to exclude the possibility of colonic damage.
3. The following unwanted effects have been reported with Creon: diarrhoea, constipation, stomach pains, feeling sick, and skin reactions (rash, itching).
|
|
|
|
|
Symptoms:
|
Overdosage, although not experienced to date, could precipitate meconium ileus or other bowel obstructive symptoms.
|
|
Treatment:
|
Most cases respond to supportive measures including stopping enzyme therapy, ensuring adequate rehydration.
|
|
|
|
|
Replacement therapy in pancreatic enzyme deficiency states. The enzymes have hydrolytic activity on fat, carbohydrates and proteins.
|
|
|
|
Pharmacokinetic data are not available as the enzymes act locally in the gastro-intestinal tract. After exerting their action, the enzymes are digested themselves in the intestine.
|
|
|
|
Granules:
Macrogol 4000
Hypromellose phthalate
Triethyl citrate
Cetyl alcohol
Dimeticone.
Capsule shell:
Gelatin,
Red, yellow and black iron oxides (E172)
Titanium dioxide (E171)
Sodium lauryl sulphate
|
|
|
|
HDPE container with polypropylene cap. Containers hold 100, 250 or 300 capsules.
|
|
|
|
Abbott Healthcare Products Ltd
Mansbridge Road
West End
Southampton
S018 3JD
UK
|
|
|
|
Date of first authorisation: 21st March 1997
Date of last renewal: 21st March 2007
|
|
|
